方直科技 reported revenue of ¥0.04B for the period ended 2026-06-30, +25.2% year on year. Net income was ¥0.01B, a 14.7% net margin on a 79.5% gross margin. The largest revenue line is 自主产品 at 79% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.04B | +25.2% |
| Gross profit | ¥0.03B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | +86.3% |
| Gross margin | 79.5% | Net margin 14.7% |
| Revenue Q/Q | +5.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 自主产品 | ¥0.03B | 79.0% |
| 集成项目 | ¥0.00B | 7.1% |
| 技术开发、服务 | ¥0.00B | 6.8% |
| AI数字化产品 | ¥0.00B | 4.7% |
| 其他产品 | ¥0.00B | 2.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.01B | 20.5% |
| R&D | ¥0.01B | 26.8% |
| SG&A | ¥0.02B | 45.8% |
| Tax & other | ¥0.00B | 3.8% |
| Item | Amount |
|---|---|
| Total assets | ¥0.72B |
| Total liabilities | ¥0.01B |
| Shareholders' equity | ¥0.71B |
| Equity / assets | 98.4% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | -366% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材 ・ 迪安诊断 ・ ST天玑 ・ 宝莱特 ・ 融捷健康
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies